MiR‐133a‐3p attenuates resistance of non‐small cell lung cancer cells to gefitinib by targeting SPAG5

BACKGROUND: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), clinically used to treat patients with non‐small cell lung cancer driven by EGFR mutations. Unfortunately, EGFR‐TKI resistance has become a clinical problem for the effective treatment of NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Wang, Yueming, He, Jingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274984/
https://www.ncbi.nlm.nih.gov/pubmed/34057242
http://dx.doi.org/10.1002/jcla.23853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274984/
https://www.ncbi.nlm.nih.gov/pubmed/34057242
http://dx.doi.org/10.1002/jcla.23853

Ejemplares similares